Inhibition of interleukin-1 activity by equine synovial fluid.

This research article investigates how horse synovial fluid, a substance found in joints, contains inhibitors of Interleukin-1 (IL-1), a protein playing a role in inflammation. It also examines the impact of these inhibitors and suggests their role in maintaining joint health and potentially causing joint disease.

Investigation of Interleukin-1 Inhibitors

• The study delves into the presence of inhibitors of Interleukin-1 (IL-1), a major inflammatory protein, in equine synovial fluid. To do this, an assay involving IL-1-facilitated production of Prostaglandin E2 (PGE2) by synovial cells was employed.
• The researchers found these inhibitors both in normal synovial fluid and those from two horses with early joint diseases.

Trends in Inhibitory Patterns

• The study found that both types of IL-1 inhibitors, for IL-1 alpha and IL-1 beta, were present in normal synovial fluid and the fluid of horses with early joint diseases.
• Interestingly, the IL-1 alpha inhibitors were also evident in the fluid of two horses suffering from chronic joint diseases. However, the IL-1 beta inhibitory activity was not detected in these cases.

Specificity and Impact on PGE2 Production

• The inhibitory effect was found to be specific to IL-1. The behaviour of synovial fluid did not affect the production of PGE2 when facilitated by lipopolysaccharides, implying that the action of these inhibitors is not on PGE2 directly.
• This implies a strong correlation between the levels of IL-1 inhibitors and their specific action on the protein, reinforcing its specific role in maintaining joint health.

Physiological Role and Biological Impact

• The study suggested that the identified inhibitory activity could play a significant role in controlling IL-1 activity within joints.
• The inhibitors’ absence, particularly of IL-1 beta, may be as biologically crucial as the increased production of IL-1, hinting at a possible shift in joint health and the onset of joint diseases.